Compound Evidence File
#EC-2026-0940
Tirzepatide Oral
Filed under Oral Tablets. The bureau holds 86 laboratory returns for this compound from 28 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
28 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 4 | 10.0 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 4 | 10.0 | 9.9 | 10.0 | 22 May 2026 | 6 Jul 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 4 | 10.0 | 9.9 | 10.0 | 13 Mar 2026 | 9 Jul 2026 |
| BachemCASE #VI-2026-0314 | A | 4 | 10.0 | 9.9 | 10.0 | 3 Mar 2026 | 25 Jun 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 4 | 10.0 | 9.9 | 10.0 | 7 Nov 2025 | 5 May 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 3 | 10.0 | 10.0 | 10.0 | 22 Jan 2026 | 12 Jun 2026 |
| Bulk Peptide SupplyCASE #VI-2026-0446 | X | 1 | 10.0 | 10.0 | 10.0 | 28 Mar 2025 | 28 Mar 2025 |
| HomopeptideCASE #VI-2026-0760 | A | 5 | 9.9 | 9.9 | 10.0 | 24 May 2026 | 24 May 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 5 | 9.9 | 9.9 | 10.0 | 1 Jan 2026 | 12 Jul 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 4 | 9.9 | 9.9 | 10.0 | 7 Nov 2025 | 10 Jul 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 3 | 9.9 | 9.9 | 10.0 | 9 Feb 2026 | 4 Jul 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 3 | 9.9 | 9.9 | 10.0 | 6 Jan 2026 | 11 Apr 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 2 | 9.9 | 9.9 | 10.0 | 21 Mar 2026 | 2 Jul 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 2 | 9.9 | 9.9 | 10.0 | 15 Feb 2026 | 4 Jul 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 2 | 9.9 | 9.9 | 10.0 | 11 Jan 2026 | 23 Jan 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 2 | 9.9 | 9.9 | 10.0 | 11 Dec 2025 | 19 Jun 2026 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 4 | 9.2 | 8.5 | 9.7 | 24 May 2026 | 24 May 2026 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 6 | 8.6 | 7.7 | 9.4 | 24 May 2026 | 24 May 2026 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 4 | 8.6 | 7.4 | 9.1 | 24 May 2026 | 24 May 2026 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 4 | 8.3 | 6.8 | 9.4 | 21 May 2026 | 21 May 2026 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 2 | 7.8 | 7.5 | 8.1 | 24 May 2026 | 24 May 2026 |
| Modern AminosCASE #VI-2026-0635 | X | 1 | 7.4 | 7.4 | 7.4 | 25 Apr 2025 | 25 Apr 2025 |
| LiliPeptideCASE #VI-2026-0695 | X | 7 | 7.1 | 5.3 | 10.0 | 28 Mar 2025 | 25 May 2026 |
| Prime PeptidesCASE #VI-2026-0696 | X | 1 | 6.9 | 6.9 | 6.9 | 2 Apr 2025 | 2 Apr 2025 |
| Quenna PMQCASE #VI-2026-0415 | X | 1 | 5.8 | 5.8 | 5.8 | 24 Apr 2025 | 24 Apr 2025 |
| Nanjing Xiyuxun Technology XYXCASE #VI-2026-0433 | X | 1 | 5.6 | 5.6 | 5.6 | 20 Jun 2025 | 20 Jun 2025 |
| EHZ PeptidesCASE #VI-2026-0296 | C | 2 | 5.1 | 4.8 | 5.4 | 28 Mar 2025 | 21 May 2026 |
| Peptides 4 ResearchCASE #VI-2026-0511 | X | 1 | 2.7 | 2.7 | 2.7 | 13 Feb 2025 | 13 Feb 2025 |
Open any subject to view the batch-level evidence for Tirzepatide Oral alone.